Pfizer, Astellas Padcev combo shows overall survival benefit in urothelial cancer

libre de droit
- A combination of Pfizer (NYSE:PFE) and Astellas’ (OTCPK:ALPMF)(OTCPK:ALPMY) antibody-drug conjugate Padcev (enfortumab vedotin-ejfv) with Merck’s (MRK) Keytruda (pembrolizumab) demonstrated a sustained overall survival and progression-free survival benefit as a first-line therapy for urothelial cancer.
- Data showed that Padcev + Keytruda reduced the